Contact a Patient Education Liaison (PEL)

Our PELs have backgrounds in nursing and genetic counseling. They can help educate patients and families about primary hyperoxaluria type 1 (PH1) and provide information about treatment with OXLUMO™. They can also connect you to more resources and answer questions.



PELs help raise awareness about PH1 in the community and educate patients and their families by:

  • Educating patients in one-on-one meetings
  • Participating in family meetings
  • Engaging with community health organizations and advocacy groups

Register today to have a PEL reach out to you to discuss questions you may have about PH1 and/or treatment with OXLUMO. Registration is quick and easy. Simply fill out the form below.

All fields required unless otherwise noted.

*Please enter your first name
*Please enter your last name
*Please enter your street address
*Please enter your city
*Please select your state
*Please enter your ZIP / postal code
*Please enter your phone number
OK to leave voicemail. (Optional)
I would like a PEL to contact me with information about PH1 and/or a PH1 treatment.
I understand that a discussion with any Alnylam representative (including a PEL) will not take the place of any discussions I have with my physician.
I am 18 years or older.

Support and resources are available throughout your treatment journey

Find support that can help you and your family during treatment with OXLUMO.

Let’s Go


The most common side effect of OXLUMO™ (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.  

For additional information about OXLUMO, please see full Prescribing Information.